Personalis | MedPath

Personalis to Present New Data on NeXT Personal ctDNA Test for Early Cancer Detection at Major Oncology Conferences

a month ago

• Personalis and academic collaborators will showcase new clinical data on their ultrasensitive NeXT Personal ctDNA assay at upcoming AACR and ASCO conferences, demonstrating its application across multiple cancer types. • The VICTORI study will present preliminary results on post-surgical minimal residual disease detection in colorectal cancer, while the TRACERx collaboration will share findings from one of the largest ctDNA studies in early-stage lung cancer. • New research will expand clinical evidence for NeXT Personal into neoadjuvant treatment settings for breast cancer and cervical cancer, supporting the company's mission to enable earlier detection of residual and recurrent cancer.

Ultrasensitive ctDNA Test Predicts Relapse Risk and Survival in Early-Stage Lung Cancer

4 months ago

• A new ultrasensitive ctDNA test, NeXT Personal, shows promise in predicting lung cancer relapse risk and overall survival in early-stage patients. • The test, which detects circulating tumor DNA in blood, identified patients with low ctDNA levels who were less likely to relapse after surgery. • High sensitivity of NeXT Personal allowed for the detection of smaller amounts of ctDNA, improving the accuracy of risk stratification. • The findings suggest ctDNA testing could inform treatment decisions and personalize care for early-stage lung cancer patients.

ZEST Trial Halted Due to Low ctDNA Detection Rates in Early Breast Cancer

5 months ago

• The Phase III ZEST trial, evaluating niraparib for preventing breast cancer recurrence based on circulating tumor DNA (ctDNA), was terminated early due to low ctDNA detection rates. • Broad entry criteria in ZEST led to the inclusion of low-risk patients, resulting in a low rate of ctDNA positivity and hindering the trial's randomization process. • Exploratory analysis suggested a longer recurrence-free interval with niraparib in patients with low ctDNA levels at baseline, though the study was underpowered. • Future ctDNA-guided trials should focus on higher-risk patients and earlier ctDNA testing during neoadjuvant therapy to improve feasibility and outcomes.

Novel HER2-Targeted Therapies Show Promise in Advanced Breast Cancer

6 months ago

• Trastuzumab duocarmazine significantly improves progression-free survival compared to physician's choice in pretreated HER2-positive metastatic breast cancer patients. • Combining eribulin with trastuzumab and pertuzumab demonstrates non-inferior progression-free survival versus taxanes in first-line HER2-positive advanced breast cancer. • Pertuzumab retreatment with trastuzumab and chemotherapy shows a significant overall survival benefit in HER2-positive locally advanced/metastatic breast cancer.

ctDNA Testing Shows Promise in Guiding Colorectal Cancer Treatment Decisions

7 months ago

• ctDNA testing influenced adjuvant therapy decisions in 16.3% of stage II/III colorectal cancer cases, with de-escalation in 59.9% and escalation in 35.7%. • Post-operative ctDNA positivity predicts inferior disease-free survival, while ctDNA clearance is associated with superior outcomes in stage II/III CRC. • ctDNA testing demonstrates high sensitivity in detecting recurrence across various sites, including low-shedding areas like the peritoneum and lung. • Adjuvant chemotherapy benefit was evident only in MRD-positive patients, highlighting ctDNA's potential for treatment selection in stage II/III CRC.